Pembrolizumab probably leads to lower time to death from any cause (here: overall mortality at 12‐month compared with chemotherapy (moderate certainty).
Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
Sunitinib probably leads to higher progression‐free survival(absolute effect size estimates based on… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).
Sunitinib probably leads to higher overall survival (absolute effect size estimates based on survival… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (low certainty).
The review found no eligible studies for this question.